Phase II study of neoadjuvant anthracycline combined with nanoparticle albumin‑bound paclitaxel for human epidermal growth factor receptor 2‑negative breast cancer

Ishigami,Emi; Sakakibara,Masahiro; Sakakibara,Junta; Iwase,Toshiaki; Hayama,Shoko; Masuda,Takahito; Nakagawa,Ayako; Nagashima,Takeshi; Sangai,Takafumi; Fujimoto,Hiroshi; Otsuka,Masayuki

doi:10.3892/mco.2017.1464

Phase II study of neoadjuvant anthracycline combined with nanoparticle albumin‑bound paclitaxel for human epidermal growth factor receptor 2‑negative breast cancer

Authors:
- Emi Ishigami
- Masahiro Sakakibara
- Junta Sakakibara
- Toshiaki Iwase
- Shoko Hayama
- Takahito Masuda
- Ayako Nakagawa
- Takeshi Nagashima
- Takafumi Sangai
- Hiroshi Fujimoto
- Masayuki Otsuka
View Affiliations

Affiliations: Department of General Surgery, Chiba University Graduate School of Medicine, Chiba, Chiba 260‑8670, Japan
Published online on: October 20, 2017 https://doi.org/10.3892/mco.2017.1464
Pages: 1079-1082

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neoadjuvant chemotherapy (NAC) with anthracyclines followed by taxane chemotherapy has become the standard treatment for patients with locally advanced, operable breast cancer. Recently, the efficacy of nanoparticle albumin‑bound paclitaxel (nab‑PTX) for metastatic breast cancer was reported. However, there are still few studies of a neoadjuvant regimen including nab‑PTX. Thus, the present phase II study evaluated the efficacy and safety of 5‑fluorouracil, epirubicin and cyclophosphamide (FEC regimen) followed by nab‑PTX as neoadjuvant treatment for operable human epidermal growth factor receptor 2 (HER2)‑negative breast cancer. Women with operable HER2‑negative breast cancer (clinical stage T1a‑4N1‑3) received 4 cycles of FEC (5‑fluorouracil 500 mg/m2, epirubicin 100 mg/m2 and cyclophosphamide 500 mg/m2 every 21 days), followed by 4 cycles of nab‑PTX at 260 mg/m2 every 21 days. The patients then underwent mastectomy or breast‑conserving surgery (BCS). The primary endpoint was pathological complete response (pCR) rate. The secondary endpoints included clinical response rate, pathological response rate, BCS rate and safety. A total of 16 patients were evaluated and 3 patients (18%) achieved pCR (1 patient with estrogen receptor‑positive cancer and 2 with estrogen receptor‑negative cancer). The pCR rate was 12 and 25% in patients with estrogen receptor‑positive and ‑negative cancers, respectively. The clinical response rate was 100% (clinical complete and partial response in 6 and 10 patients, respectively). The BCS rate was 31.25%. Three patients experienced grade 3 neutropenia during FEC therapy, and no grade 3/4 events occurred during nab‑PTX therapy. Thus, neoadjuvant therapy with FEC followed by nab‑PTX for operable HER2‑negative breast cancer was found to be a safe and effective option.

View Figures

View References

1	Wolmark N, Wang J, Mamounas E, Bryant J and Fisher B: Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from national surgical adjuvant breast and bowel project B-18. J Natl Cancer Inst Monogr. 30:96–102. 2001. View Article : Google Scholar
2	Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL, et al: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 21:4165–4174. 2003. View Article : Google Scholar : PubMed/NCBI
3	Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil SR, et al: Preoperative chemotherapy: Updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol. 26:778–785. 2008. View Article : Google Scholar : PubMed/NCBI
4	Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, Buzdar AU, Smith IE, Symmans WF, Singh B and Winer EP: Preoperative therapy in invasive breast cancer: Pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 26:814–819. 2008. View Article : Google Scholar : PubMed/NCBI
5	Early Breast Cancer Trialists' Collaborative Group (EBCTCG), . Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, et al: Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 379:432–444. 2012. View Article : Google Scholar : PubMed/NCBI
6	FrenchAdjuvantStudy Group: Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol. 19:602–611. 2001. View Article : Google Scholar : PubMed/NCBI
7	Bonneterre J, Roché H, Kerbrat P, Brémond A, Fumoleau P, Namer M, Goudier MJ, Schraub S, Fargeot P and Chapelle-Marcillac I: Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the french adjuvant study group 05 randomized trial. J Clin Oncol. 23:2686–2693. 2005. View Article : Google Scholar : PubMed/NCBI
8	De Laurentiis M, Cancello G, D'Agostino D, Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V, Esposito A, Esposito A, et al: Taxane-based combinations as adjuvant chemotherapy of early breast cancer: A meta-analysis of randomized trials. J Clin Oncol. 26:44–53. 2008. View Article : Google Scholar : PubMed/NCBI
9	Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, et al: Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 352:2302–2313. 2005. View Article : Google Scholar : PubMed/NCBI
10	Roché H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D, Symann M, Kerbrat P, Soulié P, Eichler F, et al: Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: The FNCLCC PACS 01 trial. J Clin Oncol. 24:5664–5671. 2006. View Article : Google Scholar : PubMed/NCBI
11	Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 21:976–983. 2003. View Article : Google Scholar : PubMed/NCBI
12	Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, Wickerham DL, Yothers G, Soran A and Wolmark N: Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. J Clin Oncol. 23:3686–3696. 2005. View Article : Google Scholar : PubMed/NCBI
13	Buzdar AU, Singletary SE, Valero V, Booser DJ, Ibrahim NK, Rahman Z, Theriault RL, Walters R, Rivera E, Smith TL, et al: Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: Preliminary data of a prospective randomized trial. Clin Cancer Res. 8:1073–1079. 2002.PubMed/NCBI
14	Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M and O'Shaughnessy J: Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 23:7794–7803. 2005. View Article : Google Scholar : PubMed/NCBI
15	Blum JL, Savin MA, Edelman G, Pippen JE, Robert NJ, Geister BV, Kirby RL, Clawson A and O'Shaughnessy JA: Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer. 7:850–856. 2007. View Article : Google Scholar : PubMed/NCBI
16	Robidoux A, Buzdar AU, Quinaux E, Jacobs S, Rastogi P, Fourchotte V, Younan RJ, Pajon ER, Shalaby IA, Desai AM, et al: A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer. Clin Breast Cancer. 10:81–86. 2010. View Article : Google Scholar : PubMed/NCBI
17	Valachis A, Mauri D, Polyzos NP, Chlouverakis G, Mavroudis D and Georgoulias V: Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: A systematic review and meta-analysis. Breast. 20:485–490. 2011. View Article : Google Scholar : PubMed/NCBI
18	Shimada H, Ueda S, Saeki T, Shigekawa T, Takeuchi H, Hirokawa E, Sugitani I, Sugiyama M, Takahashi T, Matsuura K, et al: Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: Evaluation of efficacy and safety. Jpn J Clin Oncol. 45:642–649. 2015. View Article : Google Scholar : PubMed/NCBI